Literature DB >> 9012659

Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis.

M R Adams1, T C Register, D L Golden, J D Wagner, J K Williams.   

Abstract

Although estrogen replacement therapy is associated with reduced risk of coronary heart disease and reduced extent of coronary artery atherosclerosis, the effects of combined (estrogen plus progestin) hormone-replacement therapy are uncertain. Some observational data indicate that users of combined hormone replacement consisting of continuously administered oral conjugated equine estrogens (CEE) and oral sequentially administered (7 to 14 days per month) medroxyprogesterone acetate (MPA) experience a reduction in risk similar to that of users of CEE alone. However, the effects of combined, continuously administered CEE plus MPA (a prescribing pattern that has gained favor) on the risk of coronary heart disease or atherosclerosis are not known. We studied the effects of CEE (monkey equivalent of 0.625 mg/d) and MPA (monkey equivalent of 2.5 mg/d), administered separately or in combination, on the extent of coronary artery atherosclerosis (average plaque size) in surgically postmenopausal cynomolgus monkeys fed atherogenic diets and treated with these hormones for 30 months. Treatment with CEE alone resulted in atherosclerosis extent that was reduced 72% relative to untreated (estrogen-deficient) controls (P < .004). Atherosclerosis extent in animals treated with CEE plus MPA or MPA alone did not differ from that of untreated controls. Although treatment had marked effects on plasma lipoprotein patterns, statistical adjustment for variation in plasma lipoproteins did not alter the between-group relationships in atherosclerotic plaque size, suggesting that these factors do not explain substantially the atheroprotective effect of estrogen or the MPA-associated antagonism. Although the mechanism(s) remains unclear, we conclude that oral CEE inhibits the initiation and progression of coronary artery atherosclerosis and that continuously administered oral MPA antagonizes this atheroprotective effect.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9012659     DOI: 10.1161/01.atv.17.1.217

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  52 in total

Review 1.  The menopause and its treatment in perspective.

Authors:  F Al-Azzawi
Journal:  Postgrad Med J       Date:  2001-05       Impact factor: 2.401

Review 2.  The Heart and Estrogen/Progestin Replacement Study: what have we learned and what questions remain?

Authors:  G Wells; D M Herrington
Journal:  Drugs Aging       Date:  1999-12       Impact factor: 3.923

Review 3.  Postmenopausal hormone therapy, SERMs, and coronary heart disease in women.

Authors:  N K Wenger; D Grady
Journal:  J Endocrinol Invest       Date:  1999-09       Impact factor: 4.256

Review 4.  Hormones and heart disease: what we thought, what we have learned, what we still need to know.

Authors:  Marian C Limacher
Journal:  Trans Am Clin Climatol Assoc       Date:  2002

Review 5.  What is the cardioprotective role of hormone replacement therapy?

Authors:  Howard N Hodis; Wendy J Mack; Roger Lobo
Journal:  Curr Atheroscler Rep       Date:  2003-01       Impact factor: 5.113

Review 6.  Evidence-based management of dyslipidemias in women.

Authors:  John C LaRosa
Journal:  Curr Atheroscler Rep       Date:  2003-09       Impact factor: 5.113

7.  Prevention of coronary hyperreactivity in preatherogenic menopausal rhesus monkeys by transdermal progesterone.

Authors:  R Kent Hermsmeyer; Rajesh G Mishra; Dusan Pavcnik; Barry Uchida; Michael K Axthelm; Frank Z Stanczyk; Kenneth A Burry; D Roger Illingworth; Carlos Juan; Frank J Nordt
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-03-18       Impact factor: 8.311

Review 8.  Normal genetic variation, cognition, and aging.

Authors:  P M Greenwood; Raja Parasuraman
Journal:  Behav Cogn Neurosci Rev       Date:  2003-12

Review 9.  Progesterone and neuroprotection.

Authors:  Meharvan Singh; Chang Su
Journal:  Horm Behav       Date:  2012-06-23       Impact factor: 3.587

Review 10.  Sex differences in cognitive impairment and Alzheimer's disease.

Authors:  Rena Li; Meharvan Singh
Journal:  Front Neuroendocrinol       Date:  2014-01-13       Impact factor: 8.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.